open access
mTOR signaling in pediatric acute lymphoblastic leukemia and its clinical consequences
open access
Abstract
Extensive research has been conducted to identify more precise molecular and cytogenetic markers to improve risk stratification scheme and develop new targeted biological drugs in pediatric acute lymphoblastic leukemia (ALL). Activity of serine/threonine protein kinase mTOR plays a cardinal role in cell proliferation, differentiation, growth and survival. Dysregulation of mTOR signaling pathway is considered to be significant in the pathogenesis and clinical course of childhood ALL. Efficacy of mTOR inhibitors (MTI) in pediatric acute lymphoblastic leukemia has been evaluated in numerous studies. This review summarises the current knowledge of clinical relevance of mTOR signaling in childhood ALL and its potential therapeutic significance.
Abstract
Extensive research has been conducted to identify more precise molecular and cytogenetic markers to improve risk stratification scheme and develop new targeted biological drugs in pediatric acute lymphoblastic leukemia (ALL). Activity of serine/threonine protein kinase mTOR plays a cardinal role in cell proliferation, differentiation, growth and survival. Dysregulation of mTOR signaling pathway is considered to be significant in the pathogenesis and clinical course of childhood ALL. Efficacy of mTOR inhibitors (MTI) in pediatric acute lymphoblastic leukemia has been evaluated in numerous studies. This review summarises the current knowledge of clinical relevance of mTOR signaling in childhood ALL and its potential therapeutic significance.
Keywords
mTOR, acute lymphoblastic leukemia, children, mTOR inhibitors
About this articleTitle
mTOR signaling in pediatric acute lymphoblastic leukemia and its clinical consequences
Journal
Journal of Transfusion Medicine
Issue
Article type
Review paper
Pages
43-48
Published online
2015-06-22
Page views
531
Article views/downloads
4968
Bibliographic record
Journal of Transfusion Medicine 2015;8(2):43-48.
Keywords
mTOR
acute lymphoblastic leukemia
children
mTOR inhibitors
Authors
Edyta Ulińska
Michał Matysiak
